Filing Flows › Profound Medical (PROF) › Guidance & outlook
Profound Medical (PROF) guidance and outlook
Profound Medical (PROF) raised its guidance on Nov 5, 2026: Revenue $25.0M for FY2026; Gross margin 70% for FY2026. Profound Medical's 10-Q filed Nov 5, 2026 makes 8 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $25.0M | raised |
| Gross margin | FY2026 | 70% | reaffirmed |
From the earnings release filed Nov 5, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 5, 2026
- Based on our current operating plans, we expect that our existing cash and sales of our products and services will enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months from the date of the issuance of these unaudited consolidated financial statements.
- During that time, we expect that our expenses will increase, primarily due to the continued commercialization of TULSA-PRO and Sonalleve.
- We have based these estimates on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect.
- We intend to use net proceeds from the 2025 Offering to fund the continued commercialization of the TULSA-PRO system in the United States, the continued development and commercialization of the TULSA-PRO system and the Sonalleve system globally and for working capital and general corporate purposes.
- We manage liquidity risk by monitoring actual and projected cash flows.
- A cash flow forecast is performed regularly to ensure that we have sufficient cash to meet our operational needs while maintaining sufficient liquidity.
- We expect to continue to devote substantial resources to expand procedure adoption and acceptance of our products.
- The availability of equity or debt financing will be affected by, among other things, the results of R&D, our ability to obtain regulatory approvals, the market acceptance of our products, the state of the capital markets generally, strategic alliance agreements and other relevant commercial considerations.
Profound Medical's latest quarter
Profound Medical, Q3 2026: revenue $9.8M (+86% year over year), operating margin -79.6%, net loss $7.7M, operating cash flow −$5.0M. The chart follows the revenue to costs, profit and cash.
Questions
Did Profound Medical raise or lower its guidance?
Profound Medical (PROF) raised its guidance on Nov 5, 2026: Revenue $25.0M for FY2026; Gross margin 70% for FY2026.
What does Profound Medical expect?
Based on our current operating plans, we expect that our existing cash and sales of our products and services will enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months from the date of the issuance of these unaudited consolidated financial statements. During that time, we expect that our expenses will increase, primarily due to the continued commercialization of TULSA-PRO and Sonalleve. We have based these estimates on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.